ArticleCureus2025
Dysgeusia-Driven Nutritional Decline in Cirrhosis: A Case of Autoimmune Hepatitis and Primary Biliary Cholangitis.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dysgeusia, or altered taste perception, is characterized by metallic, sweet, sour, or bitter sensations that can significantly impair oral intake and contribute to malnutrition, particularly in patients with chronic illness. This report describes a 75-year-old woman with decompensated cirrhosis secondary to autoimmune hepatitis and primary biliary cholangitis (PBC), who presented with a persistent metallic taste and an unintentional 25-pound weight loss over three months. Dysgeusia began shortly after the initiation of mycophenolate mofetil (MMF) and led to reduced caloric intake, early satiety, and progressive sarcopenia. Laboratory evaluation demonstrated pancytopenia, hypoalbuminemia, and hyperbilirubinemia, consistent with decompensated cirrhosis. Zinc levels were normal (82 mcg/dL), and the patient remained compliant with supplementation, making isolated zinc deficiency an unlikely cause of her symptoms. Longitudinal assessment demonstrated parallel declines in weight, nutritional intake, and hepatic synthetic function. Imaging and alpha-fetoprotein (AFP) testing excluded hepatocellular carcinoma, and no acute complications of cirrhosis were identified. The overall clinical picture suggested that dysgeusia-associated malnutrition, likely exacerbated by medication exposure in the context of portal hypertension, contributed substantially to hepatic decompensation. This case underscores the overlooked impact of taste disturbances in cirrhotic patients and highlights the importance of early identification, medication review, and nutritional intervention to mitigate malnutrition-related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.